Literature DB >> 20577089

EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.

Kornelia Kotseva1, David Wood, Guy De Backer, Dirk De Bacquer, Kalevi Pyörälä, Zeljko Reiner, Ulrich Keil.   

Abstract

OBJECTIVE: To determine whether the 2003 Joint European Societies' guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been followed in general practice.
DESIGN: Cross-sectional survey.
METHODS: The EUROASPIRE survey was carried out in 2006-2007 in 66 general practices in 12 European countries. Patients without a history of coronary or other atherosclerotic disease either started on antihypertensive and/or lipid-lowering and/or antidiabetes treatments were identified retrospectively, interviewed and examined at least 6 months after the start of medication.
RESULTS: Four thousand, three hundred and sixty-six high-risk individuals (57.7% females) were interviewed (participation rate 76.7%). Overall, 16.9% smoked cigarettes, 43.5% had body mass index ≥30 kg/m, 70.8% had blood pressure ≥140/90 mmHg (≥130/80 in people with diabetes mellitus), 66.4% had total cholesterol ≥5.0 mmol/l (≥4.5 mmol/l in people with diabetes) and 30.2% reported a history of diabetes. The risk factor control was very poor, with only 26.3% of patients using antihypertensive medication achieving the blood pressure goal, 30.6% of patients on lipid-lowering medication achieving the total cholesterol goal and 39.9% of patients with self-reported diabetes having haemoglobin A1c ≤6.1%. The use of blood pressure-lowering medication in people with hypertension was: β-blockers 34.1%, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers 60.8%, calcium channel blockers 26.3%, diuretics 36.9%. Statins were prescribed in 47.0% of people with hypercholesterolemia. About 22.0% of all patients were on aspirin or other antiplatelet medication.
CONCLUSION: The EUROASPIRE III survey in general practice shows that the lifestyle of people being treated as high cardiovascular risk is a major cause of concern with persistent smoking and high prevalence of both obesity and central obesity. Blood pressure, lipid and glucose control are completely inadequate with most patients not achieving the targets defined in the prevention guidelines. Primary prevention needs a systematic, comprehensive, multidisciplinary approach, which addresses lifestyle and risk factor management by general practitioners, nurses and other allied health professionals, and a health care system which invests in prevention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20577089     DOI: 10.1097/HJR.0b013e3283383f30

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  56 in total

1.  Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?

Authors:  Kornelia Kotseva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

2.  Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension.

Authors:  O Petrák; T Zelinka; B Štrauch; J Rosa; Z Šomlóová; T Indra; H Turková; R Holaj; J Widimský
Journal:  J Hum Hypertens       Date:  2015-04-02       Impact factor: 3.012

Review 3.  Statins in the primary prevention of cardiovascular disease.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2013-06-04       Impact factor: 32.419

4.  HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.

Authors:  Gino Seravalle; Nevrez Koylan; Istemi Nalbantgil; Nail Caglar; Fosca Quarti-Trevano; Wim Makel; Guido Grassi; Francesco Fici
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-22

5.  The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention.

Authors:  Kornelia Kotseva
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

6.  Prevalence, awareness, and management of CKD and cardiovascular risk factors in publicly funded health care.

Authors:  Jacobien C Verhave; Stéphan Troyanov; Frédéric Mongeau; Lorraine Fradette; Josée Bouchard; Philip Awadalla; François Madore
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

Review 7.  CVD prevention in 2014: Advances in the prevention of cardiovascular disease.

Authors:  Nizal Sarrafzadegan; Carolyn Gotay
Journal:  Nat Rev Cardiol       Date:  2014-12-23       Impact factor: 32.419

8.  Follow-up of Antihypertensive Therapy Improves Blood Pressure Control: Results of HYT (HYperTension survey) Follow-up.

Authors:  F Fici; G Seravalle; N Koylan; I Nalbantgil; N Cagla; Y Korkut; F Quarti-Trevano; W Makel; G Grassi
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-05-11

9.  2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts).

Authors:  Massimo F Piepoli
Journal:  Int J Behav Med       Date:  2017-06

10.  Primary care of patients with high cardiovascular risk : Blood pressure, lipid and diabetic target levels and their achievement in Hungary.

Authors:  Endre Szigethy; Zoltán Jancsó; Csaba Móczár; István Ilyés; Eszter Kovács; László Róbert Kolozsvári; Imre Rurik
Journal:  Wien Klin Wochenschr       Date:  2013-07-04       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.